The National Institutes of Health issued a final risk assessment Friday for a controversial Boston University laboratory where researchers hope to study some of the world’s deadliest infectious diseases.
The report triggers a 30-day comment period before the agency issues a decision on whether the risk posed by the lab is acceptable. Then long-stalled legal challenges, which prompted this latest review of the biolab, could move forward in state and federal courts.
The 192,000-square-foot National Emerging Infectious Diseases Laboratory, mostly completed in 2008, was designed to study the most lethal level 4 infectious agents, such as anthrax, pneumonic plague, and ebola.
The $200 million lab received a waiver from the state in December to study less harmful diseases, such as hepatitis and salmonella, while the legal proceedings continue. That work has begun.
An e-mailed statement from Boston University called the assessment released Friday “thorough and comprehensive.”
Community members and concerned organizations, including the Conservation Law Foundation, have maintained that risk analysis to date has been insufficient, failing to take into account unique aspects of the South End and nearby Roxbury neighborhoods.
Jennifer Rushlow, a lawyer with the foundation, said Friday that she would not comment on specifics of the final assessment without more time to review it.But she said that an earlier draft had failed to account for the fact that the lab is located in a neighborhood where residents have been disproportionately exposed to environmental hazards.
An NIH summary of that draft had said the risk of infections to the general public was “extremely low, or beyond reasonably foreseeable,” with the exception of a secondary infection from an influenza or SARS, which is still deemed unlikely during the 50-year expected lifetime of the lab.
The report is available for viewing online and at the South End, Grove Hall, and Dudley libraries and at the Boston Public Library’s central branch on Boylston Street.
Comments may be mailed to the attention of NEIDL Risk Assessment, National Institutes of Health, 6705 Rockledge Drive, Suite 750, Bethesda, MD 20892-7985.